Secukinumab for psoriasis in a patient with hepatitis B

Brittany Feaster; Abigail Cline; Steven R Feldman

Secukinumab for psoriasis in a patient with hepatitis B

Dermatol Online J. 2018 Sep 15;24(9):13030/qt58t2f0jh.

Authors

Brittany Feaster¹, Abigail Cline, Steven R Feldman

Affiliation

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. bfeaster@scmail.spelman.edu.

PMID: 30677838

Abstract

The case reported describes a 48-year-old man with congenital hepatitis B receiving secukinumab for treatment of psoriasis. Some biologic therapies have been associated with an increased risk of reactivation of hepatitis B. In the case of this patient, secukinumab has successfully managed his psoriasis without evidence of hepatitis B virus reactivation.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Dermatologic Agents / adverse effects*
Dermatologic Agents / therapeutic use
Hepatitis B / chemically induced*
Hepatitis B / complications
Hepatitis B / congenital
Humans
Male
Middle Aged
Psoriasis / complications
Psoriasis / drug therapy*
Virus Activation / drug effects

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
secukinumab